PBGENE PMM
Alternative Names: PBGENE-PMMLatest Information Update: 29 Sep 2023
At a glance
- Originator Precision Biosciences
- Class DNA; Endoribonucleases; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mitochondrial myopathies
Most Recent Events
- 27 Sep 2023 Precision Biosciences receives patent allowance for PBGENE-PMM in USA
- 12 Sep 2023 Precision Biosciences expects to submit a CTA and/or IND for PBGENE PMM for Mitochondrial myopathies in 2025
- 12 Sep 2023 Precision Biosciences plans a clinical trial for PBGENE PMM for Mitochondrial myopathies